Bruker Corporation filings document financial results, capital returns, governance actions and proxy matters for a scientific instruments and diagnostics company.
Recent Form 8-K disclosures cover quarterly and annual operating results, outlook commentary, segment information for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, and dividends on common stock and 6.375% Mandatory Convertible Preferred Stock, Series A. The definitive proxy statement covers board elections, executive compensation, pay-versus-performance data, shareholder voting items and governance practices. Other material-event filings record board composition changes and executive transition arrangements.
Bruker Corporation (BRKR) will add Eicke Latz, MD, PhD, to its board effective January 1, 2027. The board approved the appointment on November 13, 2026, and expanded the board by one seat to 12 directors; Latz is assigned to Class II and will initially serve until the 2029 Annual Meeting of Stockholders. Latz has co-founded five biotechnology companies and is Scientific Director of the German Rheumatology Research Center and Professor of Experimental Rheumatology at Charité Universitätsmedizin Berlin.
Bruker declared a quarterly cash dividend of $0.05 per share on its common stock. It is payable January 7, 2027, to shareholders of record at the close of business on December 21, 2026.
Bruker Corporation completed a reorganization of its four reportable segments effective July 1, 2026. The new BSI BIOS segment combines the BioSpin, SciY and Chemspeed Technologies divisions formerly in BSI BioSpin with the Daltonics and Optics divisions formerly in BSI CALID; it also includes Mimetas, a division formed in the third quarter of 2026 after Bruker acquired a majority interest in Mimetas B.V. BSI Microbiology and Infection Diagnostics (BMID) now groups Microbiology, Molecular Diagnostics and Biomedical Systems, formerly in BSI CALID. BSI NANO and BEST retained their existing segment structures.
Bruker supplied recast segment schedules for the fiscal years ended December 31, 2024 and 2025, plus quarterly and year-to-date periods through September 30, 2025 and periods in 2026 through June 30. The recast data aligns historical segment reporting with the new structure. Bruker states the realignment did not affect historical consolidated results of operations, financial position or cash flows, and the recast information is not a restatement of previously issued financial statements.
Bruker Corporation reported third-quarter 2026 revenue of $874.0 million, versus $860.5 million a year earlier, while net loss attributable to common shareholders was $122.8 million, versus $62.4 million. For the nine months ended September 30, 2026, revenue was $2,535.9 million versus $2,459.3 million, and common-shareholder net loss was $182.2 million versus $37.4 million. Operating cash flow for the nine months was $112.0 million, compared with net cash used in operating activities of $95.7 million.
Goodwill impairment charges were $174.5 million in the third quarter and $309.4 million for the nine months, versus $96.5 million in each prior-year period; the third-quarter charge represented the remaining goodwill of the BSB&CA reporting unit. Bruker’s 2026 acquisitions involved $141.8 million in total consideration transferred, net of cash acquired, including the remaining 60.0% of Tofwerk and 94% of Mimetas. Acquired businesses contributed $32.8 million of revenue and $2.6 million of pretax losses from their acquisition dates through September 30, 2026. A segment reorganization effective July 1, 2026, did not affect historical consolidated results, financial position or cash flows.
Bruker Corporation reported third-quarter 2026 revenue of $874.0 million, up 1.6% year over year, with organic revenue growth of 0.7%. Non-GAAP diluted EPS was $0.56, up 24.4%, and non-GAAP operating margin was 16.3%, compared with 12.3% a year earlier. GAAP diluted loss per share was $(0.81), versus $(0.41), and results included a $174.5 million non-cash goodwill impairment charge.
Bruker Scientific Instruments revenue rose 0.8% to $793.9 million, while its organic revenue declined 0.4%; Bruker Energy & Supercon Technologies revenue increased 11.2% to $82.1 million, with organic growth of 11.8% net of intercompany eliminations. For the first nine months, revenue was $2.54 billion, up 3.1%, while organic revenue declined 0.3%; non-GAAP diluted EPS was $1.36 versus $1.23, and GAAP diluted loss per share was $(1.20) versus $(0.25).
Bruker reconfirmed FY2026 revenue guidance of $3.52 billion to $3.56 billion, including organic growth of 1% to 2%, and non-GAAP EPS guidance of $2.10 to $2.15. It expects reported revenue growth of 2.5% to 3.5%, with foreign currency neutral to revenue, compared with a previously expected 0.5% tailwind.
Bruker Corporation’s Board of Directors declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. Declared October 29, 2026, the dividend is payable December 1, 2026, to shareholders of record at the close of business on November 15, 2026.
Bruker Corp (BRKR) officer Mark Munch, Executive Vice President and President of Bruker Nano Inc., exercised options for 2,000 shares of common stock on September 15, 2026 at an exercise price of $22.19 per share and sold the 2,000 acquired shares at $52.87 per share the same day. The stock option, originally granted on October 4, 2016, fully covered these 2,000 shares and was reported as having no remaining balance after the exercise. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Bruker Corporation (BRKR) reports that officer Mark R. Munch has filed a notice under Rule 144 to sell 2,000 shares of Bruker common stock through Morgan Stanley Smith Barney on NASDAQ. The planned sale has an indicated aggregate market value of $105,740 based on the filing data.
The notice states that Bruker had 152,359,316 shares of common stock outstanding as of September 15, 2026. The filing also lists prior sales by Munch of 2,000 shares on July 15, 2026 and 2,000 shares on August 14, 2026, with reported aggregate values of $120,500 and $115,200, respectively.
BRUKER CORP (BRKR) reported equity compensation awards to officer Burkhard Prause. He received a grant of 3,303 shares of Common Stock in the form of Restricted Stock Units, which vest in equal installments on the first, second, third, and fourth anniversaries of the August 15, 2026 grant date. He was also granted Stock Options for 2,678 shares of Common Stock at an exercise price of $57.70 per share, vesting on the same four annual schedule and expiring on August 15, 2036. Following the Common Stock grant, his directly held Common Stock position is 28,461 shares.
Bruker Corp (BRKR) reported insider equity transactions by Wolfgang Pusch, President BMID Group. On August 17, 2026, he sold 3,473 shares of Common Stock at $56.90 per share. On August 15, 2026, he received equity awards: 3,120 Restricted Stock Units that vest in four equal annual installments, and 2,529 stock options with a $57.70 exercise price, also vesting in four equal annual installments and expiring on August 15, 2036.
BRUKER CORP (symbol: BRKR) is the issuer of record for a Form 4 filing submitted to the SEC.